The most important contraceptive manufacturer on the Romanian market, Gedeon Richter announces the availability on the market of a new emergency contraceptive, EllaOne, effective for a period of 5 days after unprotected sexual contact or failure of a conventional contraceptive method. EllaOne is already available in pharmacies, where it can be purchased on prescription, issued by your family doctor or a specialist doctor.
The new contraceptive is just as effective as levonorgestrel on the first day (95%).
Research studies on the efficacy of this new contraceptive have been conducted in 80 clinics in Europe and the United States in a sample of 4,000 participants. The monitoring was done by 33 of the most reputable women health experts worldwide. The results of the studies certify EllaOne as the only emergency contraceptive that has proven contraceptive efficacy by day five after unprotected sexual contact.
Two of the world's most prestigious medical journals, The Lancet and Obstetrics & Gynecology, published in February 2010 the results of last-minute clinical studies on EllaOne. The contraceptive contains ulipristal acetate, a new active substance, which belongs to the class of selective synthetic modulators of progesterone receptors. EllaOne received marketing authorization in the European Union in 2009 and is already present in 17 countries.
Produced by the French company HRA Pharma, EllaOne is present in Romania through the pharmaceutical company Gedeon Richter, the only manufacturer offering products for emergency contraception. Through this collaboration, Gedeon Richter expands its range of contraceptive products already available on the Romanian market. Currently, the French company HRA Pharma is conducting clinical studies regarding the use of the active substance ulipristal acetate and in the treatment of gynecological conditions such as uterine fibroids.
The newest emergency contraceptive is available in pharmacies in Romania at a price of 108.33 RON.
June 14, 2010